SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-022152
Filing Date
2023-05-15
Accepted
2023-05-15 15:16:39
Documents
89
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q srne-20230331.htm   iXBRL 10-Q 3197860
2 EX-31.1 srne-ex31_1.htm EX-31.1 17069
3 EX-31.2 srne-ex31_2.htm EX-31.2 15711
4 EX-32.1 srne-ex32_1.htm EX-32.1 26142
  Complete submission text file 0000950170-23-022152.txt   13439953

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT srne-20230331_cal.xml EX-101.CAL 110204
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT srne-20230331_def.xml EX-101.DEF 324515
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT srne-20230331_pre.xml EX-101.PRE 490534
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT srne-20230331_lab.xml EX-101.LAB 581168
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT srne-20230331.xsd EX-101.SCH 74352
83 EXTRACTED XBRL INSTANCE DOCUMENT srne-20230331_htm.xml XML 2929357
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36150 | Film No.: 23921308
SIC: 2836 Biological Products, (No Diagnostic Substances)